| [1] |
McQuade RM, Stojanovska V, Bornstein JC. Colorectal cancer chemotherapy: the evolution of treatment and new approaches [J].Current medicinalchemistry, 2017, 24(15): 1537-1557.
|
| [2] |
Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin [J]. Molecular Cancer Therapeutics, 2002, 1(3): 227-235.
|
| [3] |
Mort R, Mo L, McEwan C, et al. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer [J]. British Journal of Cancer, 2003, 89(2): 333-337.
|
| [4] |
Usanova S, Piée-Staffa A, Sied U, et al.Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression [J].Mol cancer, 2010, 9: 248.
|
| [5] |
Stordal B, Davey R.ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [J].Cancer Chemother Pharmacol, 2009, 63(4): 661-672.
|
| [6] |
Stiegelbauer V, Perakis S, Deutsch A, et al. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer [J]. World J Gastroenterol, 2014, 20(33): 11727-11735.
|
| [7] |
Kjersem JB, Ikdahl T, Lingjaerde OC, et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment [J]. Mol Oncol, 2014, 8(1): 59-67.
|
| [8] |
Beretta GL, Benedetti V, Cossa G, et al. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin [J].Biochem Pharmacol, 2010, 79(8): 1108-1117.
|
| [9] |
Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors [J].Cancer Cell, 2009, 16(6): 510-520.
|
| [10] |
Ye Y, Zhu L, Ma Y, et al. Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging [J]. Bioorg Med Chem Lett, 2011, 21(4): 1146-1150.
|
| [11] |
Teesalu T, Sugahara KN, Ruoslahti E. Tumor-penetrating peptides [J]. Frontiers in oncology, 2013, 3: 216.
|
| [12] |
Alberici L, Roth L, Sugahara KN, et al. De novo design of a tumor-penetrating peptide [J]. Cancer Research, 2013, 73(2): 804-812.
|
| [13] |
Teesalu T, Sugahara KN, Kotamraju VR, et al.C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration [J].Proc Natl Acad Sci U S A., 2009, 106(38): 16157-16162.
|
| [14] |
Zanuy D, Kotla R, Nussinov R, et al.Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor [J].J Struct Biol, 2013, 182(2): 78-86.
|
| [15] |
Prud′homme GJ, Glinka Y.Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity [J].Oncotarget, 2012, 3(9): 921-939.
|
| [16] |
Pang HB, Braun GB, Friman T, et al.An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability [J].Nat Commun, 2014, 5: 4904.
|
| [17] |
Ruoslahti E.Tumor penetrating peptides for improved drug delivery [J].Adv Drug Deliv Rev,2017, 110-111: 3-12.
|
| [18] |
Sugahara KN, Teesalu T, Karmali PP, et al.Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs[J].Science, 2010, 328(5981): 1031-1035.
|
| [19] |
Thayanithy V, Dickson EL, Steer C, et al.Tumor-stromal cross talk: direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes [J].Trans Res, 2014, 164(5): 359-365.
|
| [20] |
Connor Y, Tekleab S, Nandakumar S, et al.Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype [J].Nat commun, 2015, 6: 8671.
|
| [21] |
Sugahara KN, Braun GB, de Mendoza TH, et al.Tumor-penetrating iRGD peptide inhibits metastasis [J].Mol Cancer Ther, 2015, 14(1): 120-128.
|
| [22] |
Maione F, Capano S, Regano D, et al.Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice [J]. J Clin Invest, 2012, 122(5): 1832-1848.
|
| [23] |
Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases [J].Nat Rev Drug Discov, 2011, 10(6): 417-427.
|